Topical antiseptic/astringent: oxidation of bacterial/fungal structures and precipitation of surface proteins; deodorising effect.
Strong oxidant (Mn7+ → Mn4+): oxidises disulphide bonds and protein groups of microorganisms; precipitation of exudate proteins dries the lesion surface.
No significant systemic absorption through intact skin; increased absorption via mucosae and extensive broken skin.
Not applicable (topical use); Mn7+ reduced to MnO2 (brown) on skin; if ingested: severe tissue oxidation (methaemoglobinaemia, GI necrosis).
Not applicable (localised topical use).
No documented drug–drug interactions for this medicine.
No documented food or drink interactions.
With prolonged use/large occlusive compresses, permanganate can cause oxidative haemolysis in G6PD-deficient patients (rare but reported).
Avoid extensive, prolonged baths/compresses in G6PD-deficient patients.
EMC-UK — Potassium permanganate (BC) tablets/PIL: cutaneous use precautions; SPS NHS.
No entry in the Annex 1; potassium permanganate is a topical antiseptic/astringent (diluted 1:10,000 baths for wounds and dermatitis) with negligible systemic absorption. No restriction in pregnancy for external topical use; never ingest or apply concentrated (chemical burn risk).
Compatible for external topical use at the correct dilution (1:10,000 — pale pink solution).
Compatible; negligible absorption; avoid applying to the breasts (the infant may ingest residues).
Prontuário Terapêutico INFARMED — 13.2 (Antiseptics): potassium permanganate 1:10,000 baths (l. 32106, 33641).
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
